In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi

被引:82
作者
González, GM
Fothergill, AW
Sutton, DA
Rinaldi, MG
Loebenberg, D
机构
[1] Univ Autonoma Nuevo Leon, Dept Microbiol, Fac Med, Colonia Mitras Ctr, Monterrey 64460, NL, Mexico
[2] Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA
[3] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA
[4] Schering Plough Res Inst, Kenilworth, NJ USA
关键词
fluconazole; itraconazole; posaconazole; ravuconazole; voriconazole;
D O I
10.1080/13693780500088416
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The in vitro activities of three new triazoles were determined and compared to those of itraconazole and fluconazole against 306 clinical isolates of Blastomyces dermatitidis, Cladophialophora carrionii, Coccidioides immitis, Fonsecaea pedrosoi, Fusarium spp., Histoplasma capsulatum, Paecilomyces lilacinus, Pseudallescheria boydii and Sporothrix schenckii. Minimum inhibitory concentrations ( MIC) were determined by a broth macrodilution method of the National Committee for Clinical Laboratory Standards M38-A procedure. Itraconazole ( geometric mean MIC, 0.16-0.65 mu g/ml), voriconazole ( geometric mean MIC, 0.18-1.44 mu g/ml), ravuconazole ( geometric mean MIC, 0.18-1.09 mu g/ml), and posaconazole ( geometric mean MIC, 0.18-1.38 mu g/ml), had relatively uniform values showing potent in vitro inhibitory activity against B. dermatitidis, C. carrionii, C. immitis, F. pedrosoi, H. capsulatum, and S. schenckii. The in vitro activity was variable with strains of P. boydii, P. lilacinus and Fusarium spp.
引用
收藏
页码:281 / 284
页数:4
相关论文
共 22 条
[1]   Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species [J].
Arikan, S ;
Lozano-Chiu, M ;
Paetznick, V ;
Nangia, S ;
Rex, JH .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (12) :3946-3951
[2]  
BRADDLEY JW, 2001, CLIN INFECT DIS, V32, P1319
[3]   In vitro activities of four novel triazoles against Scedosporium spp. [J].
Carrillo, AJ ;
Guarro, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) :2151-2153
[4]   Paecilomyces lilacinus fungemia in an adult bone marrow transplant recipient [J].
Chan-Tack, KM ;
Thio, CL ;
Miller, NS ;
Karp, CL ;
Ho, C ;
Merz, WG .
MEDICAL MYCOLOGY, 1999, 37 (01) :57-60
[5]   Susceptibilities of clinical and laboratory isolates of Blastomyces dermatitidis to ketoconazole, itraconazole, and fluconazole [J].
Chapman, SW ;
Rogers, PD ;
Rinaldi, MG ;
Sullivan, DC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :978-980
[6]   Efficacy of ravueonazole in treatment of mucosal candidosis in SCID mice [J].
Clemons, KV ;
Stevens, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) :3433-3436
[7]   COCCIDIOIDOMYCOSIS DURING HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - A REVIEW OF 77 PATIENTS [J].
FISH, DG ;
AMPEL, NM ;
GALGIANI, JN ;
DOLS, CL ;
KELLY, PC ;
JOHNSON, CH ;
PAPPAGIANIS, D ;
EDWARDS, JE ;
WASSERMAN, RB ;
CLARK, RJ ;
ANTONISKIS, D ;
LARSEN, RA ;
ENGLENDER, SJ ;
PETERSEN, EA .
MEDICINE, 1990, 69 (06) :384-391
[8]   In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts [J].
Galgiani, JN ;
Lewis, ML .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :180-183
[9]  
GALLIS HA, 1990, REV INFECT DIS, V12, P308
[10]   Case Report. Atypical cutaneous pseudallescheriosis refractory to antifungal agents [J].
Ginter, G ;
Petutschnig, B ;
Pierer, G ;
Soyer, HP ;
Reischle, S ;
Kern, T ;
de Hoog, S .
MYCOSES, 1999, 42 (7-8) :507-511